Journal article icon

Journal article

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial

Abstract:

This phase II / III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza vaccine (Split virion) I.P. (TetIV) developed indigenously in the country for the first time by M/s Cadila Healthcare Limited, India containing two influenza A and two influenza B strains, one of each, Yamagata (B/Phuket) and Victoria (B/Brisbane) lineage and also compare it to that of an licensed seasonal Trivalent Influenza vaccine (TriIV) of Sanofi Pasteur India Private L...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1080/21645515.2018.1441654

Authors


Prajapati, V More by this author
Expand authors...
Cadila Healthcare Limited More from this funder
Publisher:
Taylor and Francis Publisher's website
Journal:
Human Vaccines and Immunotherapeutics Journal website
Volume:
14
Issue:
6
Pages:
1362-1369
Publication date:
2018-03-21
Acceptance date:
2018-02-20
DOI:
EISSN:
2164-554X
ISSN:
2164-5515
Pubs id:
pubs:847762
URN:
uri:708edd91-2a42-4707-8c9d-31cbfa4f3b44
UUID:
uuid:708edd91-2a42-4707-8c9d-31cbfa4f3b44
Local pid:
pubs:847762

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP